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Abstract
Serum amyloid A (SAA) is an evolutionary highly conserved acute phase protein that is pre-
dominantly secreted by hepatocytes. However, its role in liver injury and fibrogenesis has
not been elucidated so far. In this study, we determined the effects of SAA on hepatic stel-
late cells (HSCs), the main fibrogenic cell type of the liver. Serum amyloid A potently acti-
vated IκB kinase, c-Jun N-terminal kinase (JNK), Erk and Akt and enhanced NF-κB-
dependent luciferase activity in primary human and rat HSCs. Serum amyloid A induced the
transcription of MCP-1, RANTES and MMP9 in an NF-κB- and JNK-dependent manner.
Blockade of NF-κB revealed cytotoxic effects of SAA in primary HSCs with signs of apopto-
sis such as caspase 3 and PARP cleavage and Annexin V staining. Serum amyloid A
induced HSC proliferation, which depended on JNK, Erk and Akt activity. In primary hepato-
cytes, SAA also activated MAP kinases, but did not induce relevant cell death after NF-κB
inhibition. In two models of hepatic fibrogenesis, CCl4 treatment and bile duct ligation,
hepatic mRNA levels of SAA1 and SAA3 were strongly increased. In conclusion, SAA may
modulate fibrogenic responses in the liver in a positive and negative fashion by inducing
inflammation, proliferation and cell death in HSCs.
Introduction
Serum amyloid A (SAA) is a 12.5 kd acute phase protein which is highly conserved among all
vertebrate species [1–3]. Serum amyloid A has been shown to play a protective role during
inflammation [4]. After infection or injury, SAA levels increase up to 1000-fold reaching
serum concentrations of up to 80 μM in total. While the majority of SAA is found in associa-
tion with high density lipoproteins, up to 15% of SAA exists in a lipid-free or lipid-poor form
[5]. Human SAA1 and SAA2, and murine SAA1, SAA2 and SAA3 are the main acute phase
SAA proteins and predominantly produced by hepatocytes, whereas SAA4 is constitutively
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expressed [6]. Hepatic acute-phase SAA production is stimulated by LPS and TNFα in a NF-
κB dependent manner, and accounts for up to 2.5% of protein produced in inflamed liver in
humans and up to 10% in other species. SAA has been suggested to play a role in inflammatory
diseases such as atherosclerosis, rheumatoid arthritis and chronic inflammatory bowel disease
[7–10]. Other studies propose functions for SAA in cholesterol transport [2, 3, 11]. Recently, it
has been demonstrated that SAA may elicit cytokine and chemokine production, cell migration
and upregulation of MMPs [6, 12–15]. On the molecular level, SAA has been shown to stimu-
late several proinflammatory and anti-apoptotic signaling pathways including NF-κB, C/EBP,
JNK, Erk, Akt and p38 [10, 14–16]. Its role in liver injury and fibrogenesis is, however, yet ill-
defined.
In this study, we investigate whether SAA may be involved in a potential crosstalk between
hepatocytes as its major producing cell type and hepatic stellate cells (HSCs). HSCs are a peri-
cyte-like cell population in the liver that normally store a large proportion of the body’s vitamin
A. Following hepatic injury, HSCs undergo an activation process to become the predominant
extracellular matrix producing cell population [17, 18]. Here we demonstrate that SAA levels
are strongly elevated in 2 mouse models of hepatic fibrosis, and that SAA elicits inflammation,
proliferation and apoptosis in HSCs suggesting SAA as a potential mediator of hepatocyte-
HSC crosstalk in the injured liver.
Experimental Procedures
Cell isolation and culture
Primary HSCs were isolated by a 2-step collagenase perfusion from surgical specimens of
healthy human livers (n = 3), from livers of male Sprague-Dawley rats (300–450 g, n = 20) or
male Balb/c mice (n = 15) followed by Nycodenz (Nycodenz, Oslo, Norway) two-layer discon-
tinuous density gradient centrifugation as described [19–22]. All tissues were obtained by qual-
ified medical staff, with written donor consent and the approval of the Ethics Committee of
Columbia University, according to the Declaration of Helsinki. Purity of human, rat and
mouse HSC preparations was 88, 94 and 96%, respectively, as assessed by autofluorescence at
day 2 after isolation. Hepatic stellate cells were cultured in DMEM containing 10% fetal bovine
serum and standard antibiotics on uncoated plastic tissue culture dishes. Culture-activated
human HSCs were used between passages 2 to 7. Rat and mouse HSCs were not passaged and
considered culture-activated between day 7 and 14 after isolation. Primary skin fibroblasts
were isolated from mouse from C57BL/6J wt, IL-1R knockout, TNF-R1 knockout and IL-1R,
TNF-R1 double knockout mice by skin excision and culture in DMEMmedia plus 10% fetal
bovine serum and antibiotics. Skin fibroblasts were used between passage 2 and 4. TRAF2- and
RIP-1-knockout MEFs (a gift from Dr. Michael Karin) have been described previously [23].
The animals were sacrificed by a lethal dose of ketamine under anesthesia. All animals received
humane care and all procedures were approved by the Columbia University Institutional Ani-
mal Care and Use Committee and the Commitee for Animal Studies in North Rhine-Westpha-
lia (LANUV 84–02.05.20.11.249) and are in accordance with the requirements set by the
National Institutes of Health and the German Protection of Animals Act.
RNA isolation from HSCs and fibrotic liver and real time PCR
Hepatic fibrosis was induced by injecting Balb/c mice with 0.5 μl CCl4/g body weight intraperi-
toneally once per week for 8 weeks or by performing bile duct ligation as previously described
[20]. Human cells were treated with recombinant human SAA (PeproTech, Rocky Hill, NJ) or
recombinant human soluble Fas receptor (sFasR, PeproTech), murine cells were treated with
recombinant human SAA or recombinant murine SAA, rmTNFα or rmIL-1β (all R&D
SAA Induces Inflammation and Apoptosis in HSCs
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Systems, Minneapolis, MN, as indicated) in the presence or absence of adenoviral GFP or
IκBsr, or SP600125 (20 μM) or LY294002 (10 μM) as described above. Recombinant human
SAA corresponds to the sequence of human SAA 1 isotype except for addition of an N-termi-
nal Met and substitution of Asp for Asn at position 60 and substitution of His to Arg at posi-
tion 71. RNA was extracted by homogenizing tissue or cells in Trizol according to the
manufacturer’s instructions (Invitrogen, Carlsbad, CA). Reverse transcription was performed
using random hexamer primers according to the manufacturer’s instructions (Amersham Bio-
sciences, Piscataway, NJ). Real time PCR was performed for 40 cycles of 15s at 95°C and 60s at
60°C using an ABI 7000 sequence detection system as described [24]. Each sample was mea-
sured in duplicate and quantification was performed by comparing the Ct values of each sam-
ple to a standard curve. Probes and primers for human RANTES, human MCP-1, human IL-8,
human MMP9, 18s, mouse SAA1, mouse SAA3 and mouse GAPDH were designed by ABI.
RANTES, MCP-1, IL-8 and MMP9 levels were normalized to 18s, SAA1 and SAA3 levels were
normalized to GAPDH and are expressed as fold induction compared to untreated control.
PCR products were partly analyzed on a 1.5% agarose gel.
ELISA for IL-8, MCP-1 and RANTES
Human HSCs were infected with AdGFP or AdIκBsr at a multiplicity of 500 particles/cell one
day before treatment or pretreated with LY294002 (10 μM), SP600125 (20 μM) or DMSO
(0.1%) for 30 minutes where indicated followed by treatment with rhSAA (5 μg/ml) for 18h.
Levels of human IL-8, MCP-1 and RANTES were determined by sandwich ELISA (R&D Sys-
tems) as previously described [25].
Western Blot Analysis
Protein extracts were run on 10–12% SDS acrylamide gels and transferred onto nitrocellulose
as previously described [19–21]. Blots were incubated with anti-caspase-3, anti-PARP, anti-
phospho-Erk, anti-phospho(S536)-p65, anti-phospho(S473)-Akt (all Cell Signaling Technol-
ogy, Beverly, MA), anti-IκBα, anti-phospho(S63)-c-Jun (both Santa Cruz Biotechnology, Santa
Cruz, CA), anti-α-smooth muscle actin (αSMA, Sigma-Aldrich, St. Louis, MO) overnight at
4°C. After incubation with secondary horseradish-peroxidase conjugated antibodies (Santa
Cruz Biotechnology), the bands were visualized by the enhanced chemiluminescence light
method (Amersham Biosciences) and exposed to X-omat film (Eastman Kodak Co., New
Haven, CT) or a chemiluminescence imager (Image Station 2000R, Eastman Kodak Co.). Blots
were reprobed with monoclonal anti-actin (MP Biomedicals) or GAPDH (Cell Signaling Tech-
nology) to demonstrate equal loading.
Kinase assays
Human HSCs were serum starved for 12h followed by treatment with rhSAA or rhTNFα. IKK
activity was determined by in vitro kinase assay as previously described [19, 26]. Briefly, 300 μg
protein were immunoprecipitated with 2 μl anti-IKKγ (Santa Cruz) and washed three times.
The kinase reaction was performed in 25 μl kinase buffer containing 0.5 μCi 32P-labeled ATP,
5 μMATP and 80 μg/ml substrate (either GST-IκB (1–54), GST-p65 (354–551) or GST-p65
(354–551, 536 A) for 30 minutes at 30°C. Plasmids for GST-p65 substrates were a gift from H.
Sakurai (Tanabe Seiyaku Co., LTD., Osaka, Japan). JNK activity was determined by an in vitro
kinase assay as previously described [19]. Briefly, 25 μg of whole cell extract were precipitated
with GST-c-Jun sepharose beads, washed three times and subjected to a kinase reaction for 30
minutes at 37°C. Subsequently the beads were boiled in Laemmli-buffer and run on a 10%
SDS-acrylamide gel. The gels were stained with Coomassie blue to confirm equal substrate
SAA Induces Inflammation and Apoptosis in HSCs
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loading, dried, exposed to Kodak Biomax film and/or to a Phosphoimager (Molecular Dynam-
ics, Sunnyvale, Ca) for quantification of the bands.
NF-kB reporter assay
Human HSCs were infected with an adenovirus containing a NF-κB-driven luciferase using a
multiplicity of infection of 250 [27]. 12h later, the supernatant was changed and cells were
serum starved for 12h followed by treatment with rhSAA or rhTNFα for 6h. Luciferase activity
was detected by luminescence (Becton Dickinson, Lincoln Park, NJ) on a Fluostar Optima pla-
tereader (BMG, Durham, NC) and normalized to protein content as determined by the Brad-
ford method.
[3H]-Thymidine Incorporation Assay
Serum-starved HSCs (0.4×105/well) were incubated with rhSAA or PDGF-BB (Sigma) in the
presence or absence of PD. 16h later, the cells were pulsed with 1 μCi/ml [3H]-thymidine
(Amersham Biosciences) for 8h, followed by TCA-precipitation, lysis, and measurement in a
scintillation counter.
Determination of cell death
Activated rat HSCs were infected with AdIκBsr or AdGFP at 500 moi for 12h followed by
serum starvation for 12h and rhSAA (5 μM) or rhTNFα (R&D Systems; 10 ng/ml) treatment
for 8h. For some experiments, HSCs were co-cultured with FasL-expressing 3T3 fibroblasts or
control 3T3 fibroblasts [28] at a HSC to 3T3 ratio of 1:5. Primary mouse hepatocytes were
treated with rmSAA (5 μM) or rmTNFα (30 ng/ml, R&D Systems) with or without ActD
(0,2 μg/ml, Sigma) after 12h of serum starvation. Cell death in HSCs or hepatocytes was mea-
sured by LDH release into the culture medium according to the manufacturer’s instructions
(Roche, Indianapolis, IN). Caspase 3-cleavage and PARP cleavage were determined by western
blot. Apoptosis was visualized by fluorescent microscopy of PI- and Annexin V-staining
(Roche).
Statistical analysis
All data represent the mean of 3 independent experiments ± SD, if not otherwise stated. For
the determination of statistical significance, unpaired Student’s t-tests were performed using
Prism (GraphPad, San Diego, CA). P values of<0.05 were considered to be statistically
significant.
Results
SAA induces activation of IKK/NF-κB and JNK in primary HSCs
SAA is secreted by hepatocytes and represents one of the most abundant proteins in the liver
during the acute phase response [2, 3]. To assess whether SAA may influence the fibrogenic
response in the liver, we determined its effect on proinflammatory and anti-apoptotic pathways
in cultured HSC, which are believed to play an essential role in HSC activation and perpetua-
tion [29, 30]. First, we measured activation of IKK and JNK, which are upstream activators of
the NF-κB and the AP-1 pathways. Recombinant human SAA induced a strong activation of
IKK as determined by western blot for its target IκBα, which was completely degraded after 15
and 30 minutes of stimulation (Fig 1A). Additionally, we observed a strong S536 phosphoryla-
tion of p65, a second target of IKK. SAA also strongly induced the JNK pathway as determined
by western blotting for the phosphorylation of its target c-Jun (Fig 1A). These results were
SAA Induces Inflammation and Apoptosis in HSCs
PLOSONE | DOI:10.1371/journal.pone.0150893 March 3, 2016 4 / 17
Fig 1. SAA induces IKK and JNK activation in HSCs. A-B. Activated human HSCs were treated with recombinant human SAA (5 μM) for the indicated
times or with rhTNFα for 15 minutes. Extracts were subjected to western blot analysis using antibodies that recognize IκBα, phospho-p65 (S536), phospho-c-
Jun or actin (A). Results were confirmed by in vitro kinase assay using GST-IκBα, GST-p65, GST-p65 (S536A) and GST-c-Jun substrates (B). C. Activated
human HSCs were treated with recombinant human sFasR (10 μM) for the indicated times or with rhTNFα for 15 minutes. Extracts were analyzed by western
blot using antibodies against IκBα or GAPDH.D. Activated human HSCs were infected with adenoviruses expressing NF-κB driven luciferase followed by
treated with the indicated concentrations of SAA or with rhTNFα (10 ng/ml) for 6h. Lucerifase activity is expressed as fold induction in comparison to
untreated control. E. Primary rat HSCs were activated for 2, 4 and 8 days and treated with SAA (5 μM) or rmTNFα (30 ng/ml) for 15 minutes. Extracts were
subjected to western blot analysis using antibodies that recognize IκBα, phospho-p65 (S536), phospho-c-Jun or actin. F. Primary rat HSCs were activated for
SAA Induces Inflammation and Apoptosis in HSCs
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confirmed by an in vitro-kinase assay which showed potent activation of IKK towards
GST-IκBα and GST-p65 and JNK toward GST-c-Jun with a maximum activation occurring
after 15 minutes (Fig 1B). To rule out unspecific effects of SAA, e.g. by contaminants, we used
human recombinant soluble Fas receptor, sFasR, as control and checked for IκBα degradation.
In contrast to SAA and to TNFα as positive control, sFasR did not degrade IκBα (Fig 1C).
Notably, SAA-induced IKK and JNK activation were as potent as TNFα-induced IKK activa-
tion (Fig 1A and 1B). These results were further confirmed by a reporter gene assay in which
human HSCs were infected with an adenovirus containing 3xκB driven luciferase. SAA
induced a dose-dependent increase in NF-κB-dependent luciferase activity and exceeded the
effects of TNFα at a concentration of 10 μM (Fig 1D). Next we tested whether this effect also
occurred in primary rat HSCs. Similar to the results obtained with human HSCs, we observed a
potent activation of the JNK and IKK pathways culture-activated rat HSCs (day 4 and day 8),
but only a weak activation in quiescent HSCs (day 2) (Fig 1E). In activated rat HSCs, SAA-
induced NF-κB driven luciferase activity reached or even exceeded levels of those induced by
TNFα (Fig 1F).
SAA induces chemokine and MMP9 transcription through NF-κB and
JNK
To test whether the increased activity of IKK after SAA stimulation resulted in an increased
transcription of NF-κB dependent genes in HSCs, we measured the secretion of the NF-κB-
dependent chemokines IL-8, MCP-1 and RANTES by ELISA. Recombinant human SAA
strongly induced the secretion of all three chemokines (Fig 2A). To address the question
whether the IKK and JNK pathways are responsible for driving the induction of these chemo-
kines, we pretreated HSCs with pharmacological inhibitors of JNK and Akt, or infected them
adenovirus expressing IκBsr, a potent inhibitor of the NF-κB pathway. Whereas inhibition of
NFκB and JNK resulted in a complete or partial inhibition of chemokine secretion, respec-
tively, we did not observe a significant inhibition of chemokine secretion with the PI-3 kinase
inhibitor LY294002 (Fig 2A). Thus JNK and NF-κB, but not PI-3kinase/Akt are signaling path-
ways that mediate the upregulation of IL-8, MCP-1 and RANTES in human HSCs in response
to SAA. Next we investigated whether NF-κB and JNK inhibition also reduce chemokine pro-
duction at the mRNA level. Real time PCR measurements showed that IκBsr almost completely
reduced the SAA-induced secretion of all 3 chemokines, whereas the JNK inhibitor SP600125
reduced chemokine secretion 50 to 80% (Fig 2B). Additionally, we also investigated whether
SAA upregulated the levels MMP9 and MMP13, two crucial regulators of extracellular matrix
and inflammation in the liver [31, 32]. Whereas we did not find detectable levels of MMP13 in
the presence or absence of SAA (data not shown), we detected a strong induction of MMP9
after SAA treatment, which was blocked after incubation with either SP600125 or infection
with AdIκBsr (Fig 2C, upper panel). The induction of MMP9 by SAA was confirmed by zymo-
graphy which showed an increased MMP9 activity after SAA or TNFα (Fig 2C panel), yet to a
much lower extent than the induction found at the mRNA level.
SAA activates Erk, Akt and JNK to induce HSC proliferation
Next we determined whether SAA activated Erk and Akt in HSCs as previously reported in
other cell types [10]. Both Akt and Erk have been implicated in HSC proliferation [33, 34]. Erk
infected with adenoviruses expressing NF-κB driven luciferase at day 3 or day 7 after plating. 18 hours after infection, cells were treated with with SAA (5 μM)
or rmTNFα (30 ng/ml) for 15 minutes. NF-κB driven luciferase was determined as described above.
doi:10.1371/journal.pone.0150893.g001
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Fig 2. SAA induces chemokine and MMP 9 expression in HSCs in an NF-κB- and JNK-dependent manner in HSCs. Activated human HSCs were
treated with rhSAA in the prescence or absence of JNK inhibitor SP600125 (20 μM), or after infection with adenoviruses expressing either IκBsr or GFP. A.
24 hours after rhSAA treatment, supernatants were analyzed for MCP-1, IL-8 and RANTES secretion by ELISA.B-C. 6 hours after rhSAA treatment, RNA
was extracted and analyzed for mRNA levels of MCP-1, IL-8 and RANTES (B) or MMP9 (C) by quantitiative real time PCR (*p<0.05 vs. SP600125 treatment
or IκBsr infection, resp.). D. 24 hours after SAA treatment, proteins were extracted and MMP9 activity was analyzed by zymography.
doi:10.1371/journal.pone.0150893.g002
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phosphorylation was strongly activated by SAA with a maximum between 5 and 30 minutes
after stimulation, and inhibited by MEK inhibitor PD98059 (Fig 3A). We observed a strong
activation of Akt after SAA as apparent by S473 phosphorylation already after 5 minutes of
stimulation which lasted for up to two hours (Fig 3B). SAA-induced Akt S473 phosphorylation
was completely blocked by the PI-3 kinase inhibitor LY294002 demonstrating that SAA-
induced Akt activation is mediated by its upstream activator PI-3 kinase. To determine
whether activation of Akt and Erk in response to SAA had any effect on HSC proliferation, we
investigated SAA-induced [3H]-thymidine uptake in the presence or absence of PI-3 kinase
and MEK inhibitors. SAA-induced a strong induction of [3H]-thymidine uptake which was
almost 60% of that induced by 5 nM PDGF (Fig 3C). Pharmacological inhibition of PI-3 kinase
Fig 3. SAA induces HSC proliferation in an Erk-, JNK- and Akt-dependent manner. A-B. Activated rat HSCs were treated with rhSAA (5 μM) for the
indicated times. Phosphorylation of Erk at threonine 202 and tyrosine 204 (A), and Akt at serine 473 (B) was determined by western blot analysis in the
absence or presence of MEK inhibitor PD98059 or PI-3 kinase inhibitor LY294002, respectively. C. Serum starved activated rat HSCs were pretreated with
PD98059 (5 μM), LY294002 (10 μM) or SP600125 (20 μM) followed by stimulation with rhSAA for 24 hours. 18 hours after stimulation cells were pulsed with
1 uCi/ml 3H-thymidine followed by TCA precipitation and measurement in a scinitillation counter.
doi:10.1371/journal.pone.0150893.g003
SAA Induces Inflammation and Apoptosis in HSCs
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and MEK as well as of JNK completely blocked SAA-induced [3H]-thymidine uptake suggest-
ing that activation of these pathways is responsible for the proliferative effects of SAA (Fig 3C).
SAA induces apoptosis after NF-κB inhibition in primary HSCs, but not in
hepatocytes
Many of the signaling pathways induced by SAA resembled those activated by TNF. There-
fore, we next investigated whether SAA induces apoptosis in HSCs. Since human HSCs are
highly resistant to TNFα-induced cell death [35], we investigated SAA-induced cell death in
primary unpassaged rat HSCs which are susceptible to TNFα-induced apoptosis after NF-κB
inhibition [36]. As expected, we did not detect an increase in cell death in primary HSCs that
were treated by SAA alone. However, when NF-κB activation was blocked by IκBsr in primary
rat HSCs, we observed almost 50% cell death after 24h of SAA treatment (Fig 4A). To deter-
mine whether cell death was apoptotic, we checked for the presence of cleaved caspase 3 and
the 89kd PARP cleavage fragment, two hallmarks of apoptosis. After 8h of SAA treatment, we
detected the occurrence of caspase-3 cleavage products at 17kd and 19kd as well as the 89kd
PARP cleavage product (Fig 4B). To confirm these results, we stained HSC with AnnexinV
and propidium iodide. After 8h of SAA, the majority of IκBsr-expressing cells were Annex-
inV-positive indicating the onset of apoptotic cell death (Fig 4C). Interestingly, SAA treat-
ment alone or after inhibition of NFκB activation by ActD did not cause cell death in primary
mouse hepatocytes (Fig 4D), indicating a possible selective induction of cell death in HSCs
and hepatocytes by SAA during hepatic injury and fibrogenesis. However, SAA treatment of
hepatocytes also led to potent phosphorylation of Erk, and c-Jun and to a lesser extent of Akt
and p65 (Fig 4E).
SAA does not signal through TNF-R1, IL-1R or TLR4
SAA signaling is not well defined and several receptors including formyl peptide receptor like
1 (FPRL1) and SR-BI have been proposed as receptors for SAA [6]. We did not see any effects
on SAA-induced JNK activation when we blocked FPRL1 signaling by pertussis toxin or SR-BI
by a blocking antibody (Fig 5A). Our previous observation showed that SAA activated path-
ways that are induced in similar manner by TNFα, and to some extent by LPS and IL-1β (Figs
1–4). To investigate whether SAA-induced signals may be due to minute contamination with
LPS, we first investigated SAA-induced p65 phosphorylation in TLR4-deficient fibroblasts.
LPS did not induce p65 phosphorylation in these cells whereas TNFα and SAA induced p65
phosphorylation effectively excluding that SAA-mediated effects were due to LPS contamina-
tion (Fig 5B). To exclude involvement of TNF-R1 and IL-1R, we treated fibroblasts deficient
in TNF-R1 and/or IL-1R with SAA. Whereas TNFα and IL-1β signaling was completely abol-
ished in these cells, SAA-induced c-Jun phosphorylation as well as UV-induced c-Jun phos-
phorylation (serving as positive control) was present demonstrating that TNF-R1 and IL-1R
are not involved in the SAA pathway (Fig 5C). Similarly, we found an induction of NF-κB p65
phosphorylation in IL-1R- and/or TNFR1-deficient cells. To explore whether SAA-induced
pathways are similar to the TNF pathway downstream of the TNF receptor at the level of
adapter molecules, we treated RIP1- and TRAF2-deficient MEFs with SAA, TNFα and IL-1β.
Whereas TNFα signaling was completely blocked in RIP1- and TRAF2-deficient cells, SAA
and IL-1β induced a strong activation of the JNK pathway (Fig 5D). In conclusion, our results
demonstrate that SAA signals through an unknown receptor in fibroblasts and this pathway is
independent of TLR4, IL-1R, TNFR1, TRAF2 and RIP1, and not sensitive to inhibition by per-
tussis toxin.
SAA Induces Inflammation and Apoptosis in HSCs
PLOSONE | DOI:10.1371/journal.pone.0150893 March 3, 2016 9 / 17
Fig 4. SAA induces apoptosis in HSCs after NF-κB inhibition. Activated rat HSCs were infected with adenoviruses expressing either GFP or IκBsr. 24
hours later, HSCs were treated with rhSAA (5 μM). A. After 18h or treatment, cell death was determined by LDH activity assay.B. Caspase 3 and PARP
cleavage were determined by western blot analysis after 8 hours of rmSAA1 treatment.C. After 8 hours of rhSAA treatment, cells were stained with Annexin
V (green) and propidium iodide (PI, red) to visualize apoptosis and necrosis.D. Primary mouse hepatocytes were serum-starved for 12h and treated with
rmSAA (5 μM), ActD (0.2 μg/ml) or rmTNFα (30 ng/ml) for 18. Cell death was determined by LDH activity assay (*p<0.05 vs. untreated vehicle control). E.
Primary mouse hepatocytes were treated with rmSAA (5 μM) for the indicated times and rmTNFα (30 ng/ml) for 120 min. Phosphorylation of Erk, Akt, p65 and
c-Jun was determined by western blot analysis.
doi:10.1371/journal.pone.0150893.g004
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Fig 5. SAA does not signal in HSCs through TLR4, IL-1R, TNF-R1 or SR-BI. A. Activated human HSCs were pretreated with pertussis toxin followed by
treatment with rhSAA (5 μM). Activation of JNK, IKK and Erk pathways was analyzed by immunoblot for p-c-Jun, p-p65 and pErk.B. Activated human HSCs
were pretreated with SR-BI blocking antibody or control antibody followed by rhSAA (5 μM) stimulation. JNK activation was analyzed by western blot using
phospho-specific antibodies for its substrate c-Jun. C. Skin fibroblasts from TLR4-sufficient C3H/HeOuJ and TRL4-deficient C3H/HeJ mice were stimulated
with rhSAA (5 mM), rmTNFα (30 ng/ml) or LPS (100 nM) followed by immunoblot for p-p65.D. Skin fibroblasts from wild-type mice, TNFRI-knockout mice, IL-
1 receptor knockout mice and from TNFRI and IL-1 receptor double knockout mice were treated with rhSAA (5 μM), rmIL-1β (5 ng/ml), rmTNFα (30 ng/ml) or
irradiated with UV (100 J/m2) Activation of IKK and JNK was determined by western blot analysis for their phosphorylation of their targets p65 and c-Jun,
respectively. E. Mouse embryonic fibroblasts from wild type mice, TRAF-2 deficient mice and RIP-1 deficient mice were treated rhSAA (5 μM), rmIL-1β (5 ng/
ml), rmTNFa (30 ng/ml) or irradiated with UV (20 J/m2). Activation of IKK and JNK was determined by western blot analysis for their phosphorylation of their
targets p65 and c-Jun, respectively.
doi:10.1371/journal.pone.0150893.g005
SAA Induces Inflammation and Apoptosis in HSCs
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Hepatic SAA1 and SAA3 levels are increased during fibrogenesis
To determine whether SAA levels are increased during hepatic fibrogenesis and may thus influ-
ence HSCs in vivo, we measured SAA mRNA levels in 2 models of hepatic fibrogenesis by
quantitative real time PCR. While SAA1 is the main acute phase SAA produced by hepatocytes,
SAA3 is predominantly produced by macrophages during the acute phase response. The levels
of SAA1 and SAA3 mRNA were induced 28-fold and 8-fold, respectively, in mice after 8 injec-
tions of CCl4 (Fig 6A). In mice that underwent bile duct ligation to induce fibrogenesis, we
measured a 55-fold and 2-fold increase in SAA1 and SAA3 mRNA three days after bile duct
ligation, respectively (Fig 6A). Five days after bile duct ligation, SAA1 and SAA3 mRNA were
increased 23-fold and 19-fold, respectively. Three weeks after bile duct ligation the mRNA lev-
els of SAA1 and SAA3 still remained elevated, but were significantly lower than at day 5. In
freshly isolated quiescent HSCs, we found only low levels of SAA1 mRNA in quiescent HSCs,
which were 76000 times lower than those of hepatocytes and attributable to the small degree of
Fig 6. SAA1 and SAA3 levels are elevated during hepatic fibrogenesis. A. Hepatic fibrosis was induced in 8 week old Balb/c mice by bile duct ligation
(n = 3 mice per time point) or by treatment with CCl4 (8 injections of 0.5 μl CCl4/g body weight, dissolved in olive oil, every 3 days, n = 4 mice/group).
Following RNA extraction and reverse transcription, mRNA levels of SAA1 and SAA3 were determined by quantitative real time PCR. Levels are expressed
as fold-induction in comparison to sham or oil control mice after normalization to 18s. B. RNA was isolated from quiescent mouse HSCs (18 hours after
plating, n = 3 independent isolations) or activated mouse HSCs (5 days after plating, n = 3 independent isolations). mRNA levels of SAA1 and SAA3 were
determined by quantitative real time PCR. Levels are expressed as fold-induction in comparison to quiescent HSCs after normalization to 18s.
doi:10.1371/journal.pone.0150893.g006
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hepatocyte contamination (data not shown). After 5 days of culture-activation, the levels of
SAA1 became undetectable in HSCs consistent with the disappearance of hepatocyte contami-
nation in culture (Fig 6b, left panel). In contrast, the levels of SAA3 were markedly upregulated
during HSC culture-activation (Fig 6b, right panel). Thus, HSCs are likely to be a target of
SAA1 and a source of SAA3 in the liver.
Discussion
Although SAA is one of the most abundantly expressed hepatic proteins during infection and
inflammatory conditions, its functions remain incompletely understood. The present study
provides evidence that SAA modulates fibrogenic responses in the liver by inducing prolifera-
tion and inflammation in HSCs under some conditions and by promoting HSC cell death
under other conditions.
Previous studies have reported that SAA exerts cytokine-like properties in many cell types.
Consistent with these observations, we detected the activation of a large number of proinflam-
matory and anti-apoptotic signaling pathways in HSCs and hepatocytes. Surprisingly, the
effects of SAA on mouse and human HSCs on pathways such as NF-κB and JNK were as strong
as those exerted by TNFα and IL-1β, one of the most potent proinflammatory cytokines in
HSCs and other cell types [19, 25]. Stimulation with SAA led to a dramatic increase in the pro-
duction of chemokines such as IL-8, MCP-1 and RANTES. To exclude that signals mediated
by SAA were due to a contamination with LPS or by TLR-agonistic activity of SAA as suggested
by recent publications [37–39], we investigated proinflammatory signaling pathways in cells
from TLR4-mutant mice. We found no difference between TLR4 wild-type and TLR4-mutant
cells effectively excluding LPS as a contaminating agonist. Additionally, we investigated
whether SAA might directly or indirectly activate receptors for TNFα or IL-1β. Again, there
was no significant inhibition of SAA signals in cells deficient for TNFR1, IL-1 receptor or both
receptors. Previous reports have suggested several receptors to mediate SAA effects, among
these FLRP-1 and SR-BI [11, 14]. However, we could not find a role for these receptors in
mediating proinflammatory effects of SAA in primary HSCs. Inflammation is tightly associated
with hepatic fibrogenesis and considered a key event that promotes the activation of HSCs [29,
40, 41]. Increased production of chemokines by HSCs allows HSCs to recruit cell populations
such as Kupffer cells whose presence is required for HSCs to fully activate [42, 43] [44]. More-
over, secretion of chemokines is thought to exert autocrine and paracrine effects on HSCs fur-
ther leading to activation and to the recruitment of additional HSCs to the site of injury [45,
46]. Thus, SAA-mediated chemokine secretion in activated HSCs is likely to contribute to
fibrogenesis and may represent a novel link between hepatocytes and HSCs in the injured liver.
Induction of HSC proliferation represents a second mechanism by which SAA may enhance
fibrogenesis in the liver. Following activation, HSCs become highly proliferative and thus
expand to a pool of activated HSCs to enhance fibrogenic responses. Accordingly, blockade of
PDGF, the most potent mitogen for HSCs, significantly reduces hepatic fibrogenesis. We
found that the pro-proliferative effects of SAA were weaker than those exerted by PDGF, yet
stronger than those reported other agonists including insulin, leptin and chemokines such as
MCP-1 and RANTES [25, 45, 47, 48]. Our results are similar to studies that show SAA-induced
proliferation in human fibroblast-like synoviocytes, and suggest that SAA may exert similar
functions in chronic inflammatory conditions of different organs.
Blockade of SAA-induced signaling pathways revealed specific functions in regards to pro-
liferation and inflammation. While NF-κB and JNK activation were required for SAA-medi-
ated proinflammatory gene expression and MMP9 expression, JNK, Akt and Erk were essential
for SAA-induced proliferation. Blocking NF-κB was more efficient in reducing chemokine
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expession than blocking JNK. These findings are similar to previous results in TNFα- and IL-
1β induced chemokine regulation in HSCs suggesting that NF-κB plays a more prominent role
in regulating these genes than the JNK/AP-1 pathway [25, 49]. Previous studies have demon-
strated that both Erk and Akt are required for HSC proliferation. Thus, our study provides evi-
dence that SAA utilizes well-characterized pathways to induce inflammatory gene expression
and proliferation in HSCs.
Amyloids are believed to be responsible for organ damage in diseases such as systemic amy-
loidosis and Alzheimer’s disease. Not only has SAA been shown to induce lysis of bacterial
cells by forming ion-channels in lipid bilayer membranes [50], but has been reported to pre-
vent cell death in eukaryotic cells [51, 52]. One study reported induction of nuclear changes
consistent with apoptotic cell death after SAA treatment, but this study did not specify the type
of SAA that was used for cell death induction nor did it provide quantification of cell death
[53]. Here we show for the first time that NF-κB can act as a switch between SAA-induced cell
death and proliferation. Similar to TNFα, SAA induced cell death in HSCs only in the absence
of NF-κB activity. Thus, it seems that the anti-apoptotic effects of NF-κB regulated genes over-
ride proapopototic signals after SAA stimulation. SAA-mediated cell death was apoptotic as
demonstrated by the appearance of caspase 3- and PARP-cleavage products and Annexin V
membrane staining. This novel function of SAA suggests that in a fashion similar to TNF, SAA
may act as double-edged sword in chronic inflammatory states: Induction of inflammation
under most conditions, but induction of cell death when NF-κB dependent genes cannot be
transcribed.
In view of the abundance of SAA in the injured liver and its upregulation not only during
liver injury but many other infectious and inflammatory conditions, it is unlikely that SAA is a
primary stimulator of HSC activation and inflammation. This notion is further supported by
our finding that SAA did not induce IκBα degradation in quiescent (day 2) HSCs and only
weak phosphorylation of the JNK target c-Jun. We therefore suggest that SAA modulates
inflammatory and proliferative response in HSCs after they have initiated the activation pro-
cess. SAA plays a similar role in other chronic inflammatory conditions and stimulates wound
healing response in atherosclerosis and rheumatoid arthritis [7, 8]. While SAA is likely to pro-
mote HSC activation under many circumstances, the induction of cell death after inhibition of
NF-κB suggest that SAA can also exert opposite effects. When the underlying liver disease is
eradicated and liver injury ceases, activated HSCs are either eliminated by induction of cell
death or by deactivation [54–57]. Recently, it has been shown that inhibition of NF-κB activa-
tion during hepatic fibrogenesis is associated with an increase in HSC cell death and accelerates
recovery from experimental liver fibrosis [30]. It is conceivable that SAA may contribute to the
increased rate of HSC apoptosis in mice treated with NF-κB inhibitors such as sulfasalazine.
Moreover, hepatocytes were not effectively killed by SAA even after NF-κB inhibition, suggest-
ing that abundant SAA production during liver injury and fibrogenesis may contribute to a
controlled clearance of activated HSCs thus leading to containment of an excessive wound
healing response.
In conclusion, our study suggests that SAA represents a novel cytokine-like molecule that
may mediate a crosstalk between hepatocytes and HSCs in the injured liver. Future studies
need to define its receptor target and to confirm the potential pro- and antifibrogenic effects of
SAA during liver fibrosis induction and resolution for potential therapeutic exploitation.
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